

Characteristic	All IgAN (n=323)	Progressive IgAN (n=191)	Stable IgAN (n=83)	Danish Control cohort (n=211)	London Control cohort (n=51)
Male/Female	214/109	127/63	51/33	110/101	25/26
Caucasian/Non-Caucasian	271/52	155/36	73/10	211/0	47/4
Median age (range) – years	48 (18-84)	48 (19-84)	48 (18-82)	35 (26-49)	31 (20-66)
Median eGFR – ml/min	52.6 (28.7-81.8)	44.2 (17.7-71.3) ¹	77.3 (47.6-106)	ND	ND
Median urine PCR – mg/mmol	44 (16-117, n=220)	46 (16-141.5, n=125)	40 (15-90, n=76)	ND	ND
Median anti-hypertensive drug classes per patient	1.6	1.6	1.4	ND	ND
Patients with ACEi/ARB, excluding dialysis patients - %	73.7 (n=199)	77.3 (n=176)	79.8 (n=83)	ND	ND
Median systolic/diastolic blood pressure – mmHg	134 (122-145) / 79 (70-88, n=294)	136 (124 - 146) ² / 79 (70-88, n=181)	128 (116 - 140) / 77.5 (70-85, n=83)	ND	ND
Median duration biopsy to recruitment (months)	56.1 (22.8-104.7)	52.2 (23.3-94.8)	68.4 (22.8-171.3)	ND	ND
Reach ESRF - %	34.9	57.5 ³	0	ND	ND
History of macroscopic haematuria - %	27.8	20.1 ³	44.9	ND	ND
Diagnosis of Henoch-Schonlein purpura - %	6.4	8.9 ³	0	ND	ND
Median serum IgA – g/l	3.4 (2.9-4, n=293)	3.3 (2.7-3.8, n=178) ⁴	3.7 (3.2-4.3, n=88)	ND	2.8 (2.2-3.2, n=57) ⁵
Median serum gd-IgA1 – AU	0.50 (0.41-0.58, n=293)	0.52 (0.42-0.59, n=178) ⁶	0.47 (0.37-0.55, n=88)	ND	0.42 (0.33-0.55, n=57) ⁷

Supplemental figure 1. Cohort characteristics.

Values within parentheses represent interquartile range and number analysed if less than the respective cohort numbers. IgAN – IgA nephropathy; ACEi - Angiotensin-converting enzyme inhibitor; ARB - Angiotensin receptor blocker; AU – arbitrary units; ESRF – End-stage renal disease; gd-IgA1 - galactose-deficient IgA1; PCR – protein:creatinine ratio; ND – Not done. ¹*P* <0.0001, ²*P* =0.0014, ³*P* <0.0001 and ⁴*P* =0.0007 vs. stable IgAN; ⁵*P* <0.0001 vs. all IgAN; ⁶*P* =0.01 vs. stable IgAN; ⁷*P* =0.015 vs. all IgAN;